Boehringer-Eli Lilly Phase III trials of empagliflozin meet primary efficacy endpoint
The primary efficacy endpoint of the studies was defined as a significant change in HbA1c from baseline compared to placebo with empagliflozin 10mg and 25mg once daily doses.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.